

Bedside Clinics in Obstetrics

6th
Edition

Clinics to Care
with Illustrations



Fully Revised and Updated as per the Latest Guidelines and Statistics



Aligned with the new NMC curriculum




Clinical Cases, Viva Voce, and Practical Examinations



Richly Illustrated with Clinical Methods, Algorithms, Tables, and Surgical Procedures



High-yield points for quick revision



Arup Kumar Majhi



JAYPEE

Contents

SECTION I

Obstetric History Taking and Examination

- 1. Writing an Obstetric Long Case1**
 - Structure of History Writing 1
 - Discussion of Points Essential for Proper Case Taking and Writing 3
 - Patient's Particulars 3
 - History 4
 - Physical Examination 6
 - Procedures of Measurement of Blood Pressure in Pregnancy 9
 - Obstetric Examination 10
 - Investigations Supplied or Required 18
 - Summary of Case 19
 - Provisional Diagnosis 19
 - Differential Diagnosis 19
- 2. Examination of External Genitalia and Vaginal Examination20**
- 3. Fetus as a Patient: Fetal Assessment24**
 - Gestational Age and Fetal Growth Assessment 24
 - Prenatal Tests to Detect Anomaly 26
 - Genetics and Genetic Testing 26
 - Fetal Congenital Anomaly 28
 - Chorionic Villus Sampling 28
 - Amniocentesis 29
 - Fetal Blood Sampling 30
 - Neural Tube Defect 31
 - Screening for Aneuploidy 32
 - Assessment of Fetal Well-Being 34
 - Biophysical Profile 35
 - Amniotic Fluid Index 36
 - Physiology of Amniotic Fluid 36
 - Antenatal Fetal Cardiotocography 37
 - Doppler Velocimetry 38
 - Cerebroplacental Ratio 39
 - Assessment of Functional Maturity of Fetus 41

SECTION II

Obstetric Long Cases

- 4. Normal Pregnancy-General Clinical Discussion43**
 - General Viva in Obstetric Cases 43
 - Case Taking and History Writing 43
 - Engagement 44
 - False Labor Pain 47
 - True Labor Pain 47
 - Diagnosis of the Onset of Labor 47
 - Causes of Acute Abdomen in Pregnancy 48
 - Risks of Elderly Primi 48
 - Problems of Teenaged Pregnancy 49
 - Diagnosis of Pregnancy 51**
 - Diagnosis of Early Pregnancy 51
 - Amenorrhea 51
 - Urinary Pregnancy Test 53
 - Hook Effect 54
 - Phantom Human Chorionic Gonadotropin 54
 - Ultrasonography Scan in Pregnancy 54
 - Anomaly Scan 55
 - Recommended Practice of Ultrasound During Antenatal Period 56
 - Diagnosis of Pregnancy by Ultrasonography 56
 - Diagnosis of Pregnancy from Second Trimester Onward 56
 - Pseudocyesis 60
 - Antenatal Care 60**
 - Preconceptional Counseling and Care 60
 - Define "Antenatal Care" 61
 - Routine Laboratory and other Investigations in Antenatal Period 63
 - Antenatal Screening Tests for Perinatal Infections 63
 - Investigations Repeated in Subsequent Checkup 64
 - Urine Test in Antenatal Period 64
 - Asymptomatic Bacteriuria 64

Procedures Conducted in First and Return Antenatal Visits	64
Minor Ailments of Pregnancy	65
Hydrorrhea Gravidarum	66
Causes of Vomiting During Pregnancy	66
Hyperemesis Gravidarum	67
Routine Advices During Pregnancy	67
Birth Preparedness and Complication Readiness (BPACR)	68
Medication and Immunization	69
Immunizations During Pregnancy	70
Vaccination in Pregnancy	70
Nutrition in Pregnancy	72
Inverted Pyramid of Antenatal Care	73
Physiological Changes During Pregnancy	74
Serum Human Chorionic Gonadotropin Level in Pregnancy	76
Human Placental Lactogen Level in Maternal Blood in Normal Pregnancy	76
5. Preeclampsia and Eclampsia (Hypertensive Disorders in Pregnancy)	78
Preeclampsia	78
History	78
Physical Examination	78
Obstetrical Examination	78
Investigations	78
Summary (Specimen Summary)	79
Provisional Diagnosis	79
Differential Diagnosis	79
Classification Hypertension Disorders in Pregnancy (HDP)	79
Gestational Hypertension	81
Chronic Hypertension	82
Categorization of Preeclampsia According to Severity	82
Risk Factors	84
Etiopathology	85
Posterior Reversible Encephalopathy Syndrome	86
Prediction of Preeclampsia and Eclampsia	87
Uterine Artery Doppler	87
Diagnosis of Preeclampsia	88
Investigations	88
Complications of Preeclampsia	89
Hellp Syndrome	89
Impending Eclampsia	90
Prevention of Preeclampsia	90
Management of Preeclampsia	91
Admission of Patient Suffering from Preeclampsia	91
Advices of Home Management	91
Following Admission	91
Management of Severe Preeclampsia	94
Time of Delivery in Pregnancy Induced Hypertension	95
Mode of Termination in Preeclampsia	95
Eclampsia	98
Steps Taken During Convulsion	98
Status Epilepticus (Eclampticus)	98
Other Causes of Convulsion During Pregnancy	98
Management of Eclampsia	98
Different Anticonvulsive Regimens	100
Recurrent Convulsion: Management	102
Antihypertensives in the Management of Eclampsia	102
Obstetric Management in Eclampsia	102
Some other Causes of Chronic Hypertension	104
6. Antepartum Hemorrhage: Placenta Previa.....	105
Diagnosis of Placenta Previa	106
Define Antepartum Hemorrhage	107
Causes of Antepartum Hemorrhage	107
Differentiating Features Between Placenta Previa and Abruptio Placentae	108
Prognosis	108
Classification of Placenta Previa	108
Placental Migration	109
Dangers of Placenta Previa	110
Management of Placenta Previa	111
7. Antepartum Hemorrhage: Abruptio Placentae (Synonyms: Accidental Hemorrhage, Placental Abruptio, and Ablatio Placentae).....	117
Patient's Particulars	117
History	117
Physical Examination	117
Obstetrical Examination	117
Investigation	117
Summary	118
Diagnosis of Abruptio Placentae	118
Define Abruptio Placentae (Accidental Hemorrhage)	119
Types of Abruptio Placentae	119
Causes	119
Risk Factors for Abruptio Placentae	119
Differentiating Features of Revealed and Concealed Variety	121
Couvelaire Uterus	121
Differential Diagnosis of Abruptio Placentae	121

Chronic Abruption–Oligohydramnios Sequence	122
Sonography to Diagnose Abruption Placentae	122
Difference Between Revealed and Concealed or Mixed Varieties of Abruption Placentae	122
Dangers of Abruption Placentae	122
Severe Abruption	122
Management of Abruption Placentae	123
Coagulation Failure in Obstetrics	125
Consumptive Coagulopathy, Disseminated Intravascular Coagulation, or Defibrination Syndrome	125
Normal Hemostasis	126
Coagulation Profile Changes in Pregnancy	126
Pathophysiology of Disseminated Intravascular Coagulation	126
Diagnosis of Disseminated Intravascular Coagulation	127
Bedside Tests to Detect Coagulation Disorder	127
Management of Disseminated Intravascular Coagulation	128
Causes of Disseminated Intravascular Coagulation in Obstetrics	130
8. Prolonged Pregnancy (Post-Term Pregnancy, Postmature Pregnancy, and Postdated Pregnancy)	132
History	132
Physical Examination	132
Obstetrical Examination	132
Vaginal Examination	132
Investigations	133
Summary of Case	133
Provisional Diagnosis	133
Define Prolonged Pregnancy, Postmaturity, Post-Term Pregnancy, and Postdated Pregnancy	133
Predisposing Factors of Post-Term Pregnancy	133
Pathophysiology of Post-Term Pregnancy	133
Hazards of Postdated Pregnancy	134
Diagnosis of Postmaturity	135
Prevention of Late-Term and Post-Term Pregnancies	136
Management of Prolonged Pregnancy	136
Management of Labor in Prolonged Pregnancy	138
9. Fetal Growth Restriction/Intrauterine Growth Restriction/Small for Gestation Age.....	139
History	139
Physical Examination	139
Obstetrical Examination	139
Vaginal Examination	140
Investigations	140
Summary of Case (Specimen Summary)	140
Provisional Diagnosis	140
Diagnosis of Fetal Growth Restriction	140
Definition of Fetal Growth Restriction in a Current Pregnancy [Royal College of Obstetricians and Gynaecologists (RCOG), 2024]	143
Types of Fetal Growth Restriction	145
Etiological Factors of Fetal Growth Restriction	146
Karyotyping and Serological Screening	147
Assessment of Fetal Well-Being	147
Assessment of Fetal Functional Maturity	147
Prediction and Prevention of Fetal Growth Restriction	147
Management of Fetal Growth Restriction	151
Stage-Based Protocol (Barcelona)	155
Key Points in Management of Fetal Growth Restriction	157
10. Pregnancy with Prior Cesarean Delivery (Pregnancy with Previous Cesarean Section Pregnancy)	158
History	158
Physical Examination	158
Obstetrical Examination	158
Investigations	158
Summary (Sample Summary)	158
Provisional Diagnosis	159
Scar Integrity	160
Mode of Delivery in a Patient with Prior Cesarean Section	162
Labor Management in Postcesarean Section Pregnancy	163
Uterine Scar Rupture	165
Impending Scar Rupture	165
Scar Tenderness	166
Diagnosis of Scar Rupture	166
How Will You Manage after Rupture Uterus	168
Mode of Delivery in Intrauterine Fetal Death in a Pregnancy with Prior Cesarean Section	168
11. Intrauterine Fetal Death/Stillbirth	169
Patient's Particulars	169
History	169
Physical Examination	170
Obstetrical Examination	170
Summary of the Case (Specimen Summary)	170
Provisional Diagnosis	170

Diagnosis of IUD	171
Complications of Intrauterine Fetal Death	173
Management of Intrauterine Fetal Death	175
Management of Pregnancy with Previous History of Stillbirth	180
Timing and Mode of Delivery	182
12. Breech	183
Patient's Particulars	183
History	183
Physical Examination	183
Obstetric Examination	183
Summary of the Case	184
Imaging	186
Etiologies	186
Types of Breech	186
Incidence	187
Star-gaze Fetus	187
Complications of Breech Presentation	187
Antenatal Management	188
External Cephalic Version	188
Mechanism of Labor in Breech	190
Mode of Delivery in Breech Presentation	193
Intranatal Management	193
13. Transverse Lie.....	205
Patient's Particulars	205
Physical Examination	205
Obstetric Examination	205
Investigation	206
Summary of the Case	206
Provisional Diagnosis	207
Different Positions of Transverse Lie	208
Etiology	208
Management of Pregnancy with Transverse Lie	210
Transverse Lie with Mature Baby in Labor	210
Neglected Shoulder Presentation	211
Internal Podalic Version	212
14. Twin Pregnancy (Multifetal Gestation, Multiple Pregnancy)	214
Patient's Particulars	214
History	214
Physical Examination	214
Obstetrical Examination	215
Summary of the Case (Example)	215
Provisional Diagnosis	215
Investigation	215
Differential Diagnosis	216
Diagnosis of Twin Pregnancy	216
Conditions Where the Height of the Fundus Becomes More Than POA	216
Role of Sonography in Twin Pregnancy	217
Complications of Multiple Pregnancy	217
Reasons of Postpartum Hemorrhage	219
Lie and Presentation in Twin Pregnancy	219
Management of Multiple Pregnancy	219
Indications of Cesarean Section in Multiple Pregnancy	222
Mode of Birth in Uncomplicated Monochorionic Pregnancies	222
Intranatal Management	222
Delivery of the Second Baby of the Twin	223
Third Stage	224
Examination of Placenta	224
Complications Encountered During Second Stage of Labor	224
Locked Twins	226
Incidence of Twin Pregnancy	226
Hellin's Rule	226
Difference Between Zygosity and Chorionicity	226
Embryology	227
Fetus in Fetu	227
Determination of Chorionicity	227
Determination of Zygosity	230
Twin Pregnancy with One Molar and other Normal	230
Superfetation and Superfecundation	230
Vanishing Twin/Fetus	230
Fetus Papyraceous or Compressus	231
Complex Pathologies Attributed to Monochorionic Twin	231
Twin-to-Twin Transfusion Syndrome	232
Twin Anemia Polycythemia Sequence	233
Selective Growth Restriction	233
Consequences and Management after Death of One Fetus	234
Conjoined Twin	235
Selective Fetal Reduction and Termination	237
Triplet or Higher Order Multiple Gestation	238
15. A Case of Pregnancy with Anemia.....	242
History	242
Physical Examination	242
Obstetrical Examination	243
Investigations	243
Summary (Specimen Summary)	243

Provisional Diagnosis	243
Complications of Anemia in Pregnancy	244
Causes of Anemia	245
Physiological Anemia	245
Metabolism of Iron	246
Laboratory Investigations of Anemia	248
Prevention of Iron Deficiency Anemia	250
Time of Admission of Pregnant Women with Anemia	252
Treatment of Iron Deficiency Anemia in Pregnancy	252
Megaloblastic Anemia	258
Dimorphic Anemia	259
Hemoglobinopathies	260
Sickle-cell Hemoglobinopathies	260
Thalassemia	263
16. A Case of Pregnancy with Heart Disease	265
Patient's Particulars	265
History	265
Physical Examination	265
Systemic Examinations	265
Obstetrical Examinations	266
Investigations	266
Summary of the Case (Specimen Summary)	266
Provisional Diagnosis	267
Prevalence of Heart Disease in Pregnancy	267
Cardiovascular Changes During Normal Pregnancy (Effect of Pregnancy on Heart)	267
Clinical Features During Normal Pregnancy which Mimic Heart Disease	267
Diagnosis of Heart Disease in Pregnancy	268
The Pregnancy Heart Team [2025 European Society of Cardiology (ESC) Guideline for Cardiovascular Diseases and Pregnancy]	269
Risk Assessment	270
Global Maternal Death due to Heart Disease	270
Fetal Risks of Maternal Cardiac Disease	271
Different Types of Heart Disease Encountered in Pregnant Women	271
Preconception Counseling	271
Cardiac Contraindications to Pregnancy	271
Management	272
Contraception	274
Indications of MTP in Pregnancy due to Heart Disease	274
Indications of Corrective Surgery of Heart Lesion During Pregnancy	274
Thromboprophylaxis	275
Specific Cardiovascular Diseases in Pregnancy	275
17. A Case of Pregnancy with Jaundice	280
Patient's Particulars	280
History	280
Physical Examination	280
Obstetric Examination	281
Investigations Supplied	281
Summary of the Case	281
Provisional Diagnosis	281
Causes of Jaundice in Pregnancy	281
Liver Diseases Encountered During Pregnancy	282
Diagnostic Markers	284
Prevalence	285
Prognosis	285
Immunological Markers of HBV and Significances	285
Serum Markers in Different Types of Hepatitis	286
Management	287
Breastfeeding in Hepatitis Infected Mother	290
Prevention of Viral Hepatitis	291
Triple Elimination of Mother-To-Child Transmission (EMTCT)	291
18. A Case of Pregnancy with Diabetes Mellitus	293
Prevalence and Magnitude of the Problem	295
Major Classification of Diabetes in General	295
Classification System of Diabetes in Pregnancy by American Diabetes Association (2017)	296
White's Classification of Diabetes in Pregnancy	296
Screening and Diagnosis of Diabetes	296
DIPSI Guideline	298
Measurement of Glycosylated Hemoglobin	299
Gestational Diabetes Mellitus	299
Management of Pregnancy with Gestational Diabetes Mellitus	300
Indication of Antidiabetic Drugs and Target Value of Blood Sugar of Medical Nutrition Therapy	301
Pharmacological Agents	301
Treatment with Insulin: Dose, Type, and Frequency of Uses	301
Antenatal Fetal Monitoring in Gestational Diabetes Mellitus	302
Obstetric Management in Gestational Diabetes Mellitus	303
Recurrence of Gestational Diabetes Mellitus	303
Pregestational Diabetes Mellitus/Overt Diabetes	303
Complications of Pregestational Diabetes Mellitus	303

Fetal Congenital Anomaly	305
Preconception Counseling	306
Management of Pregnancy with PGDM	307
Dietary Adjustment in PGDM (Medical Nutrition Therapy)	308
Treatment with Insulin: Dose, Type, and Frequency of Uses	308
Obstetric Management in PGDM	309
Breastfeeding	310
Inheritance	310
Contraception	310
Complications of Newborn	310
Grave Complications of Overt Diabetes	312
Diabetic Ketoacidosis	312

19. Pregnancy in Rh-negative Woman314

Patient's Particulars	314
History	314
Physical Examination	314
Obstetrical Examination	314
Investigations	314
Summary of the Case (Example)	314
Provisional Diagnosis	315
Isoimmunization	315
Rh Factor—Its History and Landmark Advances	315
Hemolytic Disease of the Fetus and Newborn	316
Fetomaternal Hemorrhage	316
Prevalence	316
Rhesus Blood Group System	316
Mechanism of Development of Rhesus (D) Antibodies	317
ABO Blood Group Incompatibility	317
Affection of Fetus in Rh-isoimmunized Woman	318
Approach to an Rh-negative Mother while Attending Antenatal Clinic	320
Methods of Detection and to Determine the Degree of Affection of Fetus	320
Time of Delivery in an Rh-negative Pregnant Woman	323
Summary of Management of Rh-negative Pregnancy	323
Mode of Termination	325
Labor Management	325
Investigations done with the Cord Blood	325
Immunoprophylaxis	326
Indications for Anti-D Prophylaxis in Rh(D)-negative Woman During Pregnancy	327
Prevention of Fetomaternal Hemorrhage	328
Management of Affected Newborn	330

Phototherapy	330
Exchange Transfusion	330
Grandmother Theory	331
Mirror Syndrome	331
Nonimmune Hydrops	331
Causes of Hydrops	331
Diagnostic Evaluation of Fetal Hydrops	332
Management and Prognosis	332

20. Premature Rupture of Membranes Preterm Prelabor Rupture of Membranes333

History	333
Physical Examination	333
Obstetrical Examination	333
Vaginal Examination	333
Investigations	333
Summary of the Case (Specimen Summary)	333
Prelabor Ruptures of Membranes	334
Incidence	334
Outcomes of Prom	334
Pathophysiology	334
Risk Factors	334
Etiology	335
Diagnosis of Prom	335
Complications of Prom	336
Management	337
Corticosteroids in PPROM	339
Tocolytics	340
Magnesium Sulfate	340
Recurrent Prom	340

21. Preterm Labor341

History	341
Physical Examination	341
Obstetrical Examination	341
Vaginal Examination	341
Investigations	341
Summary of the Case (Specimen Summary)	341
Diagnosis of Preterm Labor	342
Incidence of Preterm Delivery	342
Risk Factors	342
Types of Preterm Delivery	344
Prediction of Preterm Labor	344
Prevention of Preterm Labor	345
Arrest of Preterm Labor	346
Tocolysis	347
Corticosteroid in Preterm Labor	349
Magnesium Sulfate for Neuroprotection	350
Antibiotics	350

Management of Preterm Labor	351
Mode of Delivery in Preterm Labor	351
Labor Management	352
Complications of Preterm Baby	352
22. Pregnancy with Bad Obstetric History (A Pregnancy with History of Recurrent Pregnancy Loss)	354
History	354
Physical Examination	354
Obstetrical Examination	354
Vaginal Examination	354
Investigations	354
Summary of the Case (Specimen Summary)	354
Investigations to Elicit the Causes of Previous Fetal or Neonatal Loss	356
Management	356
Antiphospholipid Antibody Syndrome	356
Cervical Incompetence (Cervical Weakness, Cervical Insufficiency)	357
Recurrent Pregnancy Loss	361
Definition	361
Risk Factors of Recurrent Miscarriage (Rcog, 2023)	361
Investigation in a Case of Recurrent Miscarriage	364
Management Approach in a Case of Recurrent Miscarriage	364
23. Puerperium.....	367
History of Mother	367
Patient's Particulars	367
History	367
Examination of Mother	368
Physical Examination	368
Obstetric Examination	368
History of Baby	369
Examination of Baby	369
Investigations Supplied	369
Summary (Specimen Summary)	369
Provisional Diagnosis	369
History of Mother	369
Patient's Particulars	369
History	369
Examination of Mother	370
History of Baby	370
Examination of Baby	370
Investigations	370
Puerperium	371
Rate of Involution of the Uterus	371
Causes of Retention of Urine	372
Lochia	372
Subinvolution	373
Time of Discharge of Patient	373
Advices at the Time of Discharge	374
Postnatal Care	374
Contraception for Puerperal Mother	375
Puerperal Pyrexia	379
Puerperal Sepsis	379
Investigations for Puerperal Sepsis	381
Management of Sepsis	381
Mental Health and Psychiatric Problems in Puerperium	381
Venous Thrombosis	382
Pulmonary Embolism	383
Phlegmasia Alba Dolens (White Leg)	384
Homan's Sign	384
Breasts and Lactation	384
Anatomy of Breasts	384
Physiology of Breasts	385
Endocrinology of Lactation	385
Prolactin	385
Oxytocin	386
Correct Positioning of the Baby On the Breast	386
Colostrum	386
Problems of Breasts	387
Mastitis	387
Retracted Nipple	387
Cracked Nipple	387
Breastfeeding	388
Axillary Tail of Breasts	388
Suppression of Lactation	388
Kangaroo Mother Care	388
Umbilical Cord	389
Umbilical Sepsis	389
Oral Thrush	390
Swellings of the Head of Newborn	390
Caput Succedaneum	390
Subgaleal Hemorrhage	391
Cephalohematoma	391
Reflexes of Newborn	392
Gastroschisis	392
Congenital Problems of Newborn Requiring Immediate Surgical Intervention	392
Imperforate Anus	392
Bilious Vomiting	392
Diaphragmatic Hernia	393
Trachea-Esophageal Fistula	393

- Omphalocele 393
- Gastroschisis 393
- Open Spina Bifida 393

24. Polyhydramnios394

- History and Examination 394
- Definition 394
- Types 394
- Etiopathology 395
- Clinical Manifestations 395
- Differential Diagnosis 396
- Complications 396
- Management 396

SECTION III

Fetus and Pelvis

25. Descriptions of Fetal Skull and Fetus and Relation of Fetus with Uterus and Maternal Pelvis399

- Major Bones of Skull 399
- Sutures 399
- Fontanelles 400
- Sinciput and Occiput 401
- Pterion, Asterion, and Nasion 401
- Girdles of Contact 401
- Different Attitudes 401
- Anteroposterior Diameters of Engagement of Fetal Head 401
- Vertex 401
- Face 403
- Brow 403
- Transverse Diameters of Fetal Skull 403
- Circumferences 404
- Bisacromial Diameter 404
- Bitrochanteric Diameter 404
- Verticopodalic Diameter 404
- Sternobregmatic Diameter 404
- Molding 404
- Caput Succedaneum 405
- Lie and Attitude 406
- Segments of Pelvic Inlet 407

26. Bony Pelvis409

- Normal Pelvis 409
- False Pelvis and True Pelvis 410
- Different Parts of True Pelvis 410
- Plane of Pelvic Inlet 411
- Diameters of Pelvic Inlet 411

- Measurement of Different Diameters of Female Pelvis 412
- Plane of Greatest Pelvic Dimension 412
- Least Pelvic Dimension 413
- Obstetric Outlet 414
- Anatomical Outlet 414
- Subpubic Angle 415
- Pubic Arch 415
- Waste Space of Morris 415
- Inclination of the Pelvis 415
- Sacral Angle 415
- Posterior Sagittal Diameter 416
- Pelvic Axes 416
- Pelvic Joints 416
- Symphysis Pubis Joint 416
- Sacroiliac Joint 417
- Sacrococcygeal Joint 417
- Maternal Posture During Delivery and Role of Pelvic Joints 417
- Parent Pelvis 417
- Mixed Type of Pelvis 417
- Assessment of Pelvis 418

27. Mechanism of Normal Labor424

- Cardinal Movements of the Presentation in Normal Labor 424
- The Successive Steps 425
- Asynclitism 428

28. Abnormal/Contracted Pelvis431

- Types of Contraction 431
- Diagnosis 431
- Generally Contracted Pelvis (Small Gynecoid) 433

SECTION IV

Normal Labour

29. Terminologies, Definitions, Stages of Labor, Anatomy and Physiology of Normal Labor, and Clinical Features of Labor435

- Mechanism of Onset of Labor 436
- Diagnosis of Onset of Labor 436
- Stages of Labor 437
- Graphical Representation of Stages of Labor (Modified after Friedman, 1978) 437
- Normal Duration of Different Stages of Labor 437
- Factors Related with Labor 438
- Separation of Placenta 445
- Clinical Features of Normal Labor 445

30. Management of Normal Labor447

**Intrapartum Care for a Positive
Childbirth Experience 447**

Management of First Stage of Labor 447

Aim of Management of First Stage of Labor 447

Definition of First Stage (WHO) 448

Durations of First Stage (WHO) 448

Components of First-Stage Labor Management 448

Monitoring of Progress of Labor 451

Features of Maternal Distress 453

Features of Fetal Distress 453

**Management of Second Stage
of Labor 456**

Definition of Second Stage (WHO 2020) 456

Duration of Second Stage (WHO 2020) 456

Steps of the Management of Second Stage 456

Immediate Care of Newborn at Birth 461

APGAR Score 463

Management of Third Stage of Labor 463

Active Management of Third Stage of Labor 466

Active Management of Labor 468

31. Partography470

Modified WHO Partograph 470

Simplified Partography 477

World Health Organization Labour Care
Guide 2020 477

Paperless Partograph (Dr Ak Debidas) 486

E-partograph 486

Exercises on Modified Partography 487

**32. Obstetric Analgesia (Pain Relief in Labor and
Anesthesia in Cesarean Section).....492**

Inhalation Analgesics 493

Regional Anesthesia 494

Epidural Analgesia 495

Spinal Analgesia 496

Paracervical Block 497

Local Perineal Infiltration 497

General Anesthesia in Pregnancy and Labor 497

Clinical Case 498

SECTION V**Abnormal Labor****33. Malposition and Malpresentation501**

Occipitoposterior Position 501

Deep Transverse Arrest 507

Face Presentation 509

Brow Presentation 515

Mechanism and Management of Labor
in Breech Presentation 517

Mechanism and Management of Labor
in Transverse Lie 517

Compound Presentation 517

Umbilical Cord Accident [Cord Prolapse, Cord (Funic)
Presentation] 518

**34. Prolonged Labor, Abnormal Uterine Action,
Cervical Dystocia, Obstructed Labor,
Hydrocephalus, and Shoulder Dystocia.....521**

Prolonged Labor 521

Abnormal Uterine Action 525

Cervical Dystocia 527

Obstructed Labor 527

Congenital Anomalies of Fetus Causing Obstructed
Labor (Dystocia) 530

Shoulder Dystocia 533

35. Complications of Third Stage of Labor.....537

Complications of Third Stage of Labor 537

Postpartum Hemorrhage 537

Definition of Postpartum Hemorrhage 537

Classification of Postpartum Hemorrhage 538

Diagnosis of Postpartum Hemorrhage
(WHO 2025) 539

Traumatic Postpartum Hemorrhage – Types and
Predisposing Factors 540

Prevention of Postpartum Hemorrhage
(WHO 2025) 541

Clinical Case 542

Treatment of Postpartum Hemorrhage
(WHO 2025) 543

Retained Placenta 554

Clinical Case 554

Causes of Retained Placenta 554

Management of a Case of Retained Placenta 555

Placenta Accreta Spectrum (PAS) 557

International Federation of Gynecology and
Obstetrics (FIGO) Classification of Placenta Accreta
Spectrum (2019) 558

Incidence 558

Complications 558

Diagnosis 559

Ultrasound 559

Management of the Morbid Adherent Placenta
(Placenta Accreta Spectrum) 561

Genital Tract Trauma 567

Cervical Tear	568
Puerperal Hematoma	568
Infralevator Hematoma	568
Supralevator Hematoma	569
Secondary Postpartum Hemorrhage	569
Rectus Sheath Hematoma Following Cesarean Section	570
Inversion of Uterus	573
Complications	574
Diagnosis	574
Management	575

SECTION VI

Operations and Instruments

36. Know Your Instruments and Drugs.....	581
Long Hemostatic Forceps	584
Scissors	586
Instruments Used in Destructive Operations	593
37. Induction of Labor	597
Indications of Induction of Labor	597
Contraindications of Induction of Labor	597
Bishop Score	598
Methods of Induction of Labor	598
Complications of Induction of Labor	606
Failed Induction	606
Amnioinfusion	609
38. Dilatation and Evacuation.....	611
Different Methods of Evacuation of Uterus	611
Dilatation and Evacuation	611
Instruments	611
Indications	611
Steps of Rapid Method of D & E Operations	612
Various Mechanical and Pharmacological Methods for Preabortion Cervical Ripening	614
Complications	615
Suction and Evacuation	617
Indications	618
Steps	618
Complications	619
Manual Vacuum Aspiration	619
Steps	621
Details of the Instruments Used in Dilatation and Evacuation Operation	623
Sponge Holding Forceps	623
Rubber Catheter	623
Foley Catheter	623

Sims' Speculum	624
Cusco's Speculum	625
Allis Tissue Forceps	625
Multiple Teeth Vulsellum	625
Single Tooth Vulsellum	625
Uterine Sound	626
Cervical Dilators	626
Ovum Holding Forceps	627
Uterine Curette	628
Uterine Dressing Forceps	628

39. Medical Termination of Pregnancy.....629

Induction of Abortion	629
Medical Termination of Pregnancy Act of India	629
Indications of MTP	629
Methods of MTP	632
Preconception and Prenatal Diagnostic Techniques Act (PCPNDT Act)	638

40. Episiotomy.....640

Current Opinion Regarding use of Episiotomy	641
Indications of Episiotomy	641
Degrees of Perineal Tear (Perineal Laceration)	642
Structures Cut in Episiotomy	643
Steps of Episiotomy	643
Repair of Episiotomy	644
Complications	645
Vulval Hematoma	646
Obstetric Anal Sphincter Injuries	646
Episiotomy Wound Dehiscence	650

41. Obstetric Forceps.....651

Instrumental Vaginal Delivery or Operative Vaginal Delivery or Assisted Vaginal Delivery	651
Development of Obstetric Forceps	652
Varieties of Forceps	652
Parts of Forceps	653
Cephalic and Pelvic Application	655
Indications and Contraindications of Forceps Delivery	657
Prophylactic Forceps	657
Classification of Forceps Operations	657
Prerequisites of Assisted Vaginal Birth	658
Steps of Low Forceps Delivery	660
Outlet Forceps	663
Steps of Midforceps Delivery	664
Complications of Forceps Operation	667
Trial of Operative Vaginal Delivery	668
Failed Forceps	669

Forceps in Occipitoposterior Position	669
Forceps in Face Presentation	669
Forceps in Breech	670
Rotational Forceps	671
Procedures of Rotational Forceps Application	672
Management of Unrotated or Malrotated Occipitoposterior	672
Triple Obstetric Tragedy	675
Sir Kedarnath Das	675

42. Ventouse (Vacuum Extractor)677

Ventouse or Vacuum Extractor	677
Inventor of Ventouse	677
Different Parts of Ventouse	677
Advantages of Newer System	679
Indications of Ventouse	680
Ventouse Versus Forceps	680
Steps	680
Chignon	682
Complications of Ventouse	683
Sequential use of Instruments	683
Odon	683

43 Destructive Operations685

Relevance of Destructive Operations in Present Day Obstetrics	685
Craniotomy	685
Decapitation	689
Evisceration	690
Spondylotomy	691
Cleidotomy	691
Breech Hook and Crochet	692
Willett's Scalp Traction Forceps	692

44. Cesarean Section.....693

Instruments Used in Cesarean Section	693
Cesarean Section: What Does It Mean?	693
Types of Cesarean Section	696
Advantages of Classical Cesarean Section	696
Disadvantages of Classical Cesarean Section Over Lower Segment Cesarean Section	697
Preoperative Management for Cesarean Section	697
Amount of Blood Loss in Cesarean Section	707
Midline Vertical Skin Incision	708
Lower Uterine Segment	708
Steps of Classical Cesarean Section	709
Postoperative Care of a Patient	710
Complications of Cesarean Section	711

Maternal Mortality in Cesarean Section	712
Abdominal Distention in Postoperative Period Following Cesarean Section	712
Incidences of Cesarean Section Rate	712
Reasons of Increase in Cesarean Section Rate	713
Robson's Criteria	713
Difficult Cesarean Section (Cesarean Section in Special Situations)	714
Cesarean Section in Transverse Lie	714
Cesarean Section in Placenta Previa	714
Cesarean Section in Placenta Accreta Spectrum	714
Cesarean Section in Deeply Engaged Head	714
Patwardhan's Technique	715
Fetal Pillow	716
Cesarean Section in Floating Head	717
Cesarean Section in a Patient with a Previous CS Pregnancy	717
Cesarean Section in Parietal Adhesion	717
Obstetric Hysterectomy	718
Long Hemostatic Forceps	719
Right-angled Forceps	719
Aneurysm Needle with Thread	719

SECTION VII

Specimens

45. Placenta, Umbilical Cord, and Fetal Circulation721

Normal Placenta	721
Development of Placenta	723
Placental Barrier	727
Fetomaternal Circulation	728
Functions of Placenta	729
Abnormalities of Placenta	730
Circumvallate Placenta	730
Placenta Marginata	731
Placenta Succenturiata	732
Morbid Adhesion of Placenta (Placenta Accreta Spectrum)	733
Velamentous Insertion of Cord	734
Battledore Placenta	735
Placenta Membranacea	735
Placenta of Twin Pregnancy	736
Chorioangioma/Chorangioma	736
Umbilical Cord	737
Abnormalities of Umbilical Cord	737
True Knots of Umbilical Cord	738
Cord Round the Neck	739
Fetal Circulation	740

46. Hydatidiform Mole.....	743	48. Rupture of Uterus	775
Pathology	744	Define	775
Diagnosis of Hydatidiform Mole	744	Causes of the Rupture of Uterus	776
Cytogenetics of Molar Pregnancy	745	Diagnosis of Rupture of Uterus	777
Partial Mole and Complete Mole	746	Classification of Uterine Rupture	778
Management of Hydatidiform Mole	747	Management of a Case of Rupture of the Uterus	778
Ovarian Enlargement in Molar Pregnancy	749	Incidence of Rupture of Uterus	779
Prophylactic Chemotherapy in Hydatidiform Mole	749	Impending Rupture	781
Complications of Hydatidiform Mole	749	Colporrhexis	781
Follow-Up of Hydatidiform Mole	749	Outcome of Rupture of the Uterus	781
Criteria for Diagnosis of Postmolar Gtn	750	Prevention of Rupture of Uterus	781
High-Risk for Development of Postmolar Gestational Trophoblastic Neoplasia	750	49. Anencephaly and other Congenital Anomalies	783
Pregnancy Interval Following Hydatidiform Mole	750	Diagnosis	784
Contraception	750	Complications Due to Anencephalic Fetus	785
Twin Pregnancy with One Molar and other Normal	750	Conjoined Twin	786
Gestational Trophoblastic Disease	750	Phocomelia/Amelia	786
Types of Gestational Trophoblastic Neoplasia	751	SECTION VIII	
Diagnosis of Gestational Trophoblastic Neoplasia	751	Complications of Pregnancy and Miscellaneous	
Treatment of Gestational Trophoblastic Neoplasia	752	50. Abortion	789
Invasive Mole	753	Define Abortion	789
Choriocarcinoma	754	Classification of Abortion	789
Placental Site Trophoblastic Tumor	754	Recurrent Miscarriage	790
47. Ectopic Pregnancy	755	Early Pregnancy Loss	790
Diagnosis of Tubal Ectopic Pregnancy	756	Threatened Abortion or Miscarriage	790
Discriminatory Level of β-hCG	757	Inevitable Abortion	792
Serum Progesterone Assay	757	Incomplete Abortion	793
Dilatation and Curettage As A Diagnostic Modality	758	Complete Abortion	793
Differential Diagnosis of Acute Ectopic Pregnancy	758	Missed Abortion	794
Risk Factors of Ectopic Pregnancy	758	Blighted Ovum	794
Pathology of Tubal Ectopic Pregnancy	758	Carneous Mole	795
Management of Tubal Pregnancy	760	Etiology of Abortion	795
Expectant Management	760	Septic Abortion	796
Medical Management of Ectopic Pregnancy	760	51. Perinatal Infections.....	799
Surgical Management of Tubal Pregnancy	761	Various Infections Affecting Pregnancy	799
Management of a Case of Ruptured Tubal Pregnancy	761	Importance of Perinatal Infections	799
Conservative Surgery	762	Routes of Perinatal Transmission	799
Laparoscopy in Ectopic Pregnancy	763	Prevention of Perinatal Infections	800
Changing Trends of Ectopic Pregnancy	764	Antenatal Screening	800
Types of Ectopic Pregnancy	765	Common Causes of Vaginitis	800
		Chickenpox in Pregnancy	809
		Hookworm Infestation in Pregnancy	810
		Tuberculosis in Pregnancy	810
		HIV in Pregnancy and Childbirth and PPTCT PROGRAM	812

SECTION VIII

Complications of Pregnancy and Miscellaneous

50. Abortion789
 Define Abortion 789
 Classification of Abortion 789
 Recurrent Miscarriage 790
 Early Pregnancy Loss 790
 Threatened Abortion or Miscarriage 790
 Inevitable Abortion 792
 Incomplete Abortion 793
 Complete Abortion 793
 Missed Abortion 794
 Blighted Ovum 794
 Carneous Mole 795
 Etiology of Abortion 795
 Septic Abortion 796

51. Perinatal Infections.....799
 Various Infections Affecting Pregnancy 799
 Importance of Perinatal Infections 799
 Routes of Perinatal Transmission 799
 Prevention of Perinatal Infections 800
 Antenatal Screening 800
 Common Causes of Vaginitis 800
 Chickenpox in Pregnancy 809
 Hookworm Infestation in Pregnancy 810
 Tuberculosis in Pregnancy 810
 HIV in Pregnancy and Childbirth and PPTCT PROGRAM 812

History of HIV/AIDS and Government of India's Initiative	812
Parent-to-child Transmission	812
Causative Agents of AIDS	812
Clinical Course	813
Screening and Confirmatory Test	813
Mother-to-Child Transmission	813
Antenatal Management of Already HIV-diagnosed or Newly Diagnosed Pregnant Woman	813
Mode of Delivery in HIV-Infected Mother	815
Contraception in HIV-Positive Woman	816
Postexposure Prophylaxis	816
Triple Elimination of Mother-to-Child Transmission (HIV, Syphilis, and Hepatitis B)	817
PPTCT Program in India	817
COVID-19 Infection in Pregnancy	818
Organism	818
Transmission	818
Effect of COVID-19 on Pregnant Women	818
Vertical Transmission, Teratogenicity, and Indication of MTP	819
Categorization of COVID-19-Positive Women According to Severity	819
General Safety Measures for all Pregnant Mothers During Covid Pandemic	820
Mode of Delivery	822
Intranasal Care in COVID-Positive Woman	822
Postpartum Care	822
Prevention of COVID-19	823

52. Obstetric Emergencies824

Obstetric Shock	824
Management of Maternal Collapse	825
Components of Management Obstetric Emergencies	825
Perimortem Cesarean Section in Obstetric Collapse	825
Amniotic Fluid Embolism	825
Hemorrhagic Shock	826
Maternal Sepsis	827
Clinical Symptoms, Signs, and the Risk Factors for Diagnosis (RCOG 2024)	828
Obstetric Triage	830

53. Renal Disease and Urinary Tract Infections in Pregnancy832

Acute Kidney Injury/Acute Renal Failure in Obstetrics	832
Causes of Acute Kidney Injury in Obstetrics	832

Pathophysiology 832

Diagnosis 833

Management 833

Prognosis 834

Chronic Kidney Disease in Pregnancy 834

Pregnancy in Women Following Renal Transplantation 835

Urinary Tract Infections in Pregnancy (Urosepsis) 835

Cystitis 835

Acute Pyelonephritis 835

54. Medical Problems in Pregnancy837

Thyroid Disorder in Pregnancy 837

Hypothyroidism in Pregnancy 837

Hyperthyroidism in Pregnancy 838

Epilepsy in Pregnancy 839

Bronchial Asthma in Pregnancy 840

Systemic Lupus Erythematosus/Antiphospholipid Syndrome in Pregnancy 841

Pregnancy in OBESE Woman (Obesity in Pregnancy) 843

55. Surgical Problems in Pregnancy846

Appendicitis in Pregnancy 846

Peptic Ulcer in Pregnancy 846

Cholecystitis and Gallstone in Pregnancy 846

Pancreatitis in Pregnancy 847

Renal Stones in Pregnancy 847

56. Gynecological Diseases in Pregnancy849

Pregnancy with Uterine Fibroid

(Myoma, Fibromyoma, or Leiomyoma) 849

Diagnosis 849

Effects of Pregnancy on Fibroid Uterus 849

Effects of Fibroid on Pregnancy 850

Management of a Case of Pregnancy with Fibroid 850

Myomectomy During Cesarean Section (Cesarean Myomectomy) 851

Ovarian Tumor in Pregnancy 851

Incidence 851

Types 851

Clinical Presentation 852

Effects of Ovarian Tumor on Pregnancy and Labor 852

Effects of Pregnancy on Ovarian Tumor 853

Management 853

Cervical Cancer During Pregnancy 853

Clinical Manifestations 854

Investigations	854
Effects of Pregnancy on Ca Cervix	854
Effects of CA Cervix on the Pregnancy	854
Management	854
Mode of Delivery	854
Pregnancy with Pelvic Organ Prolapse	854

SECTION IX

Social Obstetrics

57. Social Obstetrics857

Maternal Mortality	857
Present Maternal Mortality Ratio of India	858
Global Scenario	858
Indian Scenario	858
Trends of Maternal Mortality Ratio of India	859
Causes of Maternal Death	859
Steps to Reduce Maternal Mortality	860
National and Global Strategies Taken to Improve Maternal Health and to Reduce Maternal Mortality	861
Maternal Death Review	862
Maternal Death Surveillance and Response	862
Maternal Near Miss	862
National Health Mission	862
Accredited Social Health Activist	864
Janani Suraksha Yojana	864
Janani-Shishu Suraksha Karyakram	864
Rashtriya Bal Swasthya Karyakram	865
Reproductive and Child Health Program	865
Emergency Obstetric Care (EmOC)	865
Components of Emergency Obstetric Care	866
Perinatal Mortality	867
Stillbirth and Stillbirth Rate	867
Stillbirth Rate	868
Global and Indian Scenario	868
Indian Scenario	868
Social and Biological Factors Determining PNMR	868
Causes of Perinatal Mortality	868
Navjaat Shishu Suraksha Karyakram	869
Infant Mortality Rate	869
Millennium Development Goals	869
Sustainable Development Goals (SDGS)	870
Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA)	870

Labor Room Quality Improvement Initiative (LAQSHYA)	870
Surakshit Matritva Aashwasan (SUMAN)	871
RMNCAH	872
Triple Elimination of Mother-To-Child Transmission of HIV, Syphilis, and Hepatitis B—From PMTCT to EMTCT	872

SECTION X

Diagnostic Procedures

58. Ultrasonography in Obstetrics (Imaging)875

Identify Your Ultrasonography Plates	875
Basics of Ultrasonography	877
First Trimester Sonography	879
Second Trimester Sonography	882
Third Trimester Sonography	885
Invasive Procedures	886
Number of Antenatal Ultrasound in Otherwise Normal Pregnancy	886
Fetal Vessels	886
Sonography in Labor and Delivery (Intranatal)	887
Magnetic Resonance Imaging in Obstetrics	889
Exercises of Ultrasound Findings	889

59. Intrapartum Fetal Surveillance: the Cardiotocograph893

Intrapartum Fetal Surveillance	893
Cardiotocograph	893
Information Recorded on Cardiotocograph Paper	894
Differences Between Antenatal and Labor Cardiotocographs	895
Features of Fetal Heart Rate Tracing Which are Reported From the Cardiotocograph Recording Whether Fetus is in Normal Status or There is Fetal Anoxia	895
Normal Antepartum Cardiotocograph	895
Normal Cardiotocograph Findings in Labor (FIGO)	895
National Institute for Health and Care Excellence Guideline Update 2022 in Cardiotocograph Interpretation	896
Baseline Heart Rate	898
Baseline Variability	898
Acceleration	899
Decelerations	899

Non-stress Test 900

Vibroacoustic Stimulation 900

Contraction Stress Test 900

Drawbacks of Electronic Fetal Monitoring 901

Cardiotocograph and Litigation 901

Indication of Electronic Fetal Heart Rate Monitoring
During Labor 901

Admission Cardiotocograph 901

Computerized Cardiotocography (cCTG) 902

Additional Tests for Fetal Wellbeing 902

Cardiotocograph Paper – How Will You
Interpret? 903

**Some Cardiotocographs with their
Interpretation 903**

Annexure 1—Hand Wash 907

Annexure 2—Waste Disposal Color Codes 909

Index 911

Preeclampsia and Eclampsia (Hypertensive Disorders in Pregnancy)

Chapter Outline

- History Taking
- HDP-classification
- Preeclampsia: Definition, Types
- Edema, Proteinuria
- Diagnosis
- Complications, Etiopathology, Risk factors, Organ Changes
- Prediction and Prevention of Preeclampsia (PE)
- Management of PE and Severe PE
- Antihypertensive Drugs
- Other Causes of Hypertension
- Diagnosis, Management and Complications of Eclampsia

PREECLAMPSIA

History and examination findings are to be written as in the format given in Section I. The specific points related to this case are mentioned here.

I. HISTORY

- **Patient's particulars:** Teenaged mother, elderly primigravida and low socioeconomic status are the risk factors for preeclampsia.
- **Chief complaints/History of present illness:** Enquire about persistent swelling of legs (ankle joints) or other parts of the body like face, abdominal wall, vulva or whole body and tightness of the ring on the finger.
- Headache, vomiting, pain upper abdomen, visual disturbance and low urinary output are complaints of advanced disease (Ominous symptoms/signs – page 83). M/H: As usual.
- **Present obstetric history:** Time of first detection of hypertension, any history of intake of antihypertensive drugs.
- **Past obstetric history:** History of preeclampsia or eclampsia.
- **Past history:** History of preexisting hypertension, renal disease, diabetes, thyroid disorder.
- **Family history:** Hypertension/preeclampsia.
- **Functional history:** Low urinary output is a late feature.

II. PHYSICAL EXAMINATION

- **Obesity:** Present or not.
- **Weight** (serial weight measurement is more important than a single weight).
- **Edema:** Look for all possible sites—ankle, vulva, abdomen, any facial edema.
- **Pulse:** To be seen in all four limbs.
- **BP:** Measured as outlined on page 9. Sometimes it is needed to be measured in both limbs. In coarctation of aorta, hypertension in upper extremities and normal or low blood pressure (BP) are found in lower extremities.
- **Cardiovascular system:** Examined in detail as described in chapter in “Heart disease.”
- **Ophthalmoscopic examination:** Note if findings are given (see page 87 for ophthalmic findings.)
- **Deep tendon reflexes** are assessed for hyperreflexia and the presence of clonus.

III. OBSTETRICAL EXAMINATION

There may be features of intrauterine growth restriction (IUGR) and oligohydramnios in some cases.

IV. INVESTIGATIONS

Along with other routine investigations, *urine for albumin* is the most important test. Any previous urine routine examination and microscopic examination (RE/ME) reports are asked for. Regarding special investigations,

24-hour urinary albumin, serum uric acid, liver function test, platelet count and renal function test reports are to be asked for. Collect ultrasonography (USG) report if available.

■ V. SUMMARY (SPECIMEN SUMMARY)

Mrs NB, 22 years primigravida married for _____ years coming from low S/E status admitted on _____ with swelling of legs, following amenorrhea of 39 weeks. Her last menstrual period (LMP) was _____ EDD is on _____. She stated that she first noticed the swellings over both ankle joints at about five months of pregnancy, and that the swellings did not subside in the morning. She attended antenatal clinic regularly from the third month. From 6 month onward, her blood pressure went up and she gained more weight than expected as stated by her attending doctor. She was getting antihypertensive drugs (if she gets) along with iron, folic acid, calcium and bedtime diazepam tablet. She has taken two doses of tetanus toxoid. She has no significant past history. Her father is of good health, but mother is known to be hypertensive and is on medication (if any such history).

On physical examination, her height 5 feet, and her weight is 62 kg. Pallor +, edema ++ at ankle joints and parietals, pulse—80/min, equal on all four limbs, BP—140/92 mmHg, Respiration—normal. Other cardiovascular system (CVS) examinations are within normal limits.

On obstetrical examination, height of the fundus—corresponds to term size, lie is longitudinal, cephalic presentation, and head not engaged. FHS (+) R—140/min, situated on left spinoumbilical line. Liquor seems to be adequate clinically.

Investigation reports:

- Hb—g%, blood group
- Venereal disease research laboratory (VDRL)—negative
- Urine for albumin +.

Other available investigation reports:

(Other investigations done in preeclampsia—see later).

■ VI. PROVISIONAL DIAGNOSIS

22 years primi at 39 weeks with preeclampsia.

■ VII. DIFFERENTIAL DIAGNOSIS

All causes of hypertension other than pregnancy induced hypertension will come in D/D. Some of the causes of hypertension not specific to pregnancy are described in short at the end of this chapter.

What is your diagnosis?

Give the provisional diagnosis: It is a case of preeclampsia at 39 weeks of pregnancy in a 22-year-old primigravida.

What is your case?

Describe the summary of the case.

Why are you saying—this is a case of preeclampsia?

This is a case of preeclampsia because:

- The woman has developed hypertension after 20 weeks of pregnancy detected first at the sixth month.
- Her urine is positive for albumin or
- Evidence of other multiorgan involvement, if any

■ CLASSIFICATION HYPERTENSION DISORDERS IN PREGNANCY (HDP)

How would you classify hypertension disorders in pregnancy (HDP)?

See Table 5.1.

What do you mean by hypertension?

Hypertension is diagnosed when systolic blood pressure exceeds 140 mm Hg and/or diastolic blood pressure exceeds 90 mm Hg.

What do you mean by pregnancy induced hypertension (PIH)?

Pregnancy induced hypertension is a term to describe any new-onset pregnancy-related hypertension. Accordingly, it includes gestational hypertension, preeclampsia and eclampsia.

Define Preeclampsia

What do you mean by preeclampsia?

Preeclampsia is the development of hypertension with proteinuria or with evidence of maternal organ dysfunction (liver, renal, hematological and neurological) after 20 weeks of gestation.

The diagnostic criteria for preeclampsia are given in Table 5.2.

Preeclampsia syndrome: Preeclampsia is best regarded as a pregnancy-specific syndrome which can affect almost all organ systems.

Clinical classification of preeclampsia

- Early onset: <34 weeks
- Late onset: ≥34 weeks
- Preterm onset: <37 weeks
- Term onset: ≥37 weeks

TABLE 5.1: Basic classification of hypertensive disorders of pregnancy (HDP).

Type of hypertensive disorder	Definition
Prepregnancy or at <20 weeks:	
Chronic hypertension	Hypertension detected prepregnancy or before 20 weeks' gestation
Essential	Hypertension without a known secondary cause
Secondary	Hypertension with a known secondary cause (e.g., renal disease)
White-coat hypertension	BP of ≥ 140 and/or DBP ≥ 90 mm Hg when measured in the clinic or clinic, and BP $< 135/85$ mm Hg using HBPM or ABPM readings
Masked hypertension	BP that is $< 140/90$ mm Hg at a clinic/office visit, but $\geq 135/85$ mm Hg at other times outside the clinic/office
≥ 20 weeks:	
Gestational hypertension	Hypertension arising de novo at ≥ 20 weeks' gestation in the absence of proteinuria or other findings suggestive of preeclampsia
Transient gestational hypertension	Hypertension arising at ≥ 20 weeks' gestation in the clinic, which resolves with repeated BP readings
Preeclampsia	

Note: Gestational hypertension is nonproteinuric pregnancy induced hypertension.
(ABPM: ambulatory blood pressure monitoring; HBPM: home blood pressure monitoring)
Source: From ACOG 2020.

TABLE 5.2: Diagnostic criteria for preeclampsia (ACOG 2020).

Pregnancy associated hypertension	Criteria
Blood pressure	≥ 140 mm Hg systolic or more than or equal to 90 mm Hg diastolic after 20 weeks of gestation in a woman with a previously normal blood pressure (on two occasions at least 4 hours apart) ≥ 160 mm Hg systolic or more than or equal to 110 mm Hg diastolic, severe hypertension can be confirmed within a short interval (minutes) to administer timely antihypertensive therapy
and	
Proteinuria	≥ 300 mg/24 h (or this amount extrapolated from a timed collection) or - Protein: Creatinine ratio ≥ 0.3 (each measured as mg/dL) or - Dipstick 1+ persistent (recommended only if sole available test)
or, in the absence of proteinuria, new onset hypertension with the new onset any of the followings	
Thrombocytopenia Renal insufficiency Impaired Liver function Pulmonary edema Cerebral symptoms or visual symptoms	- Platelet $< 100,000/\mu\text{L}$ ($100 \times 10^9/\text{L}$) - Serum creatinine > 1.1 mg/dL or doubling of baseline in absence of prior renal disease - Serum transaminase levels (AST or ALT) elevated twice the normal - Present - New onset headache unresponsive to medication and not accounted for by alternative diagnosis or visual symptoms, convulsions

(ALT: alanine aminotransferase; AST: aspartate aminotransferase)

Other methods of diagnosing hypertension in pregnancy?

- An increase of 30 mm Hg systolic or 15 mm Hg diastolic blood pressure from midpregnancy is used

as a diagnostic criterion of pregnancy induced hypertension even when absolute value is $< 140/90$ mm Hg. However, this increase is no longer recommended as diagnostic criteria due to lack of

strong evidence of adverse pregnancy outcomes. This group of patients should be closely observed because some of these women may experience eclamptic fit even if BP remains below 140/90 mm Hg.

- **MAP:** (By measuring *mean arterial pressure* or MAP (as advocated by Page)).

$$\text{MAP} = \frac{\text{Systolic BP} + \text{Diastolic BP} \times 2}{3}$$

When MAP is ≥ 105 mm Hg or >20 mm of previous values it signifies hypertension.

Delta hypertension

- An acute increase in mean arterial pressure (MAP) later in pregnancy is called “delta hypertension”.
- It may signify preeclampsia even when absolute value of BP is $<140/90$ mm Hg. Some of these women may develop eclampsia or HELLP syndrome.

White coat hypertension

Elevated BP near health care provider but consistently normal in the home environment i.e., $<135/85$ mm Hg. It is an independent risk factor of cardiovascular disease (chronic hypertension and PE).

Masked hypertension

Elevated BP outside the office but consistently normal in the office.

N. B. Elevated BP means a Blood pressure measurement of 140/90 mm Hg or more.

How do you record blood pressure in proper way?

See (page 9, Fig. 1.4) (Fig. 5.1).



Fig. 5.1: Recording blood pressure (BP) in semirecumbent posture.

Korotkoff phase V is considered as diastolic blood pressure in pregnancy.

Korotkoff phase I remains as systolic.

Is edema included in diagnostic criteria for preeclampsia?

No, edema is not a diagnostic criterion for preeclampsia because it occurs in too many (70%) normal pregnant women.

Is overt proteinuria an essential criterion of diagnosis of preeclampsia?

In most of the cases there will be new-onset proteinuria. However, overt proteinuria may not be a feature of preeclampsia syndrome in some women. Evidence of any multiorgan involvement like maternal thrombocytopenia, hepatic, renal, cerebral, visual disturbance and pulmonary edema is sufficient to diagnose preeclampsia even in absence of proteinuria. *This is one remarkable change of diagnostic criteria of preeclampsia in the new and updated ACOG guidelines.*

What do you mean by eclampsia?

Eclampsia is the occurrence of seizures in a woman with preeclampsia, not attributed to other causes.

■ GESTATIONAL HYPERTENSION

What is gestational hypertension?

- Gestational hypertension is diagnosed when BP reaches 140/90 mm Hg or greater for the first time during pregnancy, after 20 weeks of pregnancy, but in whom **proteinuria has not developed** or **there is no other systemic finding** (as mentioned in diagnosis of preeclampsia).
- BP returns to normal by **12 weeks** postpartum.
- Up to one third of these women subsequently develop preeclampsia syndrome which includes signs like proteinuria and/or thrombocytopenia, or symptoms such as headache or epigastric pain, visual disturbances or deranged liver function test/renal function test.
- Gestational hypertension is reclassified as “**transient hypertension**” when preeclampsia does not develop, and BP returns to normal by 12 weeks after delivery.

Management of gestational hypertension

Routine antenatal management is done with extra vigilance for appearance of any symptom and sign

of preeclampsia. If such develops, manage like preeclampsia.

Otherwise continue the pregnancy till term and there is no indication of earlier induction.

■ CHRONIC HYPERTENSION

What is chronic hypertension?

Chronic hypertension is hypertension that predates pregnancy. The diagnostic criteria are:

- BP $\geq 140/90$ mm Hg before pregnancy or diagnosed before 20 weeks' gestation not attributable to gestational trophoblastic disease.

If the woman is first seen after midpregnancy, it may be difficult to determine the type of hypertensive disorder.

Causes of chronic hypertension are essential hypertension, renal disease, pheochromocytoma, connective tissue disease, and thyrotoxicosis, etc. Some of them are described at the end of this chapter.

What is superimposed preeclampsia (Preeclampsia superimposed on chronic hypertension)?

- New-onset proteinuria ≥ 300 mg/24 hours in hypertensive women or other findings of organ dysfunction as in **Table 5.2** is diagnosed as superimposed preeclampsia (ACOG 2019).
- Superimposed preeclampsia develops earlier in comparison to pure preeclampsia. It is likely to be more severe type, and fetal growth restriction is common.

■ CATEGORIZATION OF PREECLAMPSIA ACCORDING TO SEVERITY

How would you categorize preeclampsia according to severity?

There is no consensus on using terminology for grades of severity of preeclampsia syndrome. The different terms mild, moderate, less severe, non-severe and severe are used. ACOG Task Force (2013) discouraged the use of "mild preeclampsia" as it is a progressive disease. A practical classification is "nonsevere" and "severe." The "nonsevere" includes *mild* and *moderate* varieties which are not defined individually.

Severe and nonsevere varieties are summarized below, and some differentiating points are given also in **Table 5.3**.

- **Severe preeclampsia:** It is variety of Preeclampsia which is associated with any of the following findings:
 - Systolic BP 160 mm Hg or higher, or diastolic BP of 110 mm Hg or higher on two occasions at least

4 hours interval while the patient is on bed rest (unless antihypertensive therapy is initiated).

- Thrombocytopenia
- Impaired liver function test (LFT)
- Progressive renal insufficiency
- Pulmonary edema and
- New onset cerebral or visual disturbances.
- **Nonsevere preeclampsia:** Systolic BP ≥ 140 but < 160 mm Hg or diastolic ≥ 90 but < 110 mm Hg after 20 weeks of gestation in a woman with a previously normal blood pressure (on two occasions at least 4 hours apart). To fulfill the criteria of preeclampsia proteinuria should be present.

[Although severity of preeclampsia is categorized primarily based on degree of hypertension [systolic pressure (SP) ≥ 160 mm Hg and ≥ 110 mm Hg] presence of new evidence

TABLE 5.3: Classification of gestational hypertensive disorder of pregnancy according to severity.

Features	Nonsevere variety	Severe variety
• Systolic BP	< 160 mm Hg	≥ 160 mm Hg
• Diastolic BP	< 110 mm Hg	≥ 110 mm Hg
• Proteinuria*		
• Convulsion	May or may not be present	May or may not be present
– New onset-cerebral or visual disturbance	Nil	Present
– Headache	Nil	Present
– Eye symptoms	Nil	Present
• Impaired liver function		
– Elevated liver enzymes (serum transaminases) elevation	Minimal	Marked
– Severe persistent right upper quadrant or epigastric pain is not responding to medication or not due to other disease	Absent	Present
• Progressive renal insufficiency	Absent	Present
– Oliguria (≤ 400 mL of urine/24 h)		
– Serum creatinine	Normal	Elevated
• Thrombocytopenia ($< 100,000/\mu\text{L}$)	Absent	Present
• Pulmonary edema	Absent	Present

*Massive proteinuria (> 5 g) has been eliminated from consideration of preeclampsia as severe as recent studies show minimal relationship between the quantity of urinary protein and pregnancy outcome.

of any of the above organ dysfunctions along with <160 mm Hg or diastolic <110 mm Hg, should also be considered as having severe disease (ACOG)].

Classification of Gestational hypertensive disorder of pregnancy according to severity is given on Table 5.3.

What are the ominous symptoms or signs of preeclampsia?

Symptoms:

- Severe headache
- Visual disturbance such as blurring or flashing
- Epigastric or right upper quadrant pain
- Vomiting
- Sudden swelling of face hands and feet.

Signs:

- Oliguria
- Thrombocytopenia
- Renal and cardiac involvement.

Causes of swelling of legs (edema) during pregnancy (Fig. 5.2)

Physiological: Most common.

Pathological:

- Preeclampsia/eclampsia
- Hypoproteinemia/malnutrition/severe anemia
- Nephrotic syndrome
- Cardiac failure.

What are the sites to see edema?

- Leg
- Vulva (Fig. 5.3)



Fig. 5.2: Edema leg.

- Abdomen (parietes)
- Face

What are the characteristics of physiological edema?

- Usually mild, confined to lower limb, more common in right leg due to dextrorotation of uterus.
- Disappears after 12 hours rest.
- Not associated with other features of preeclampsia. (See also page 66)

What are the other causes of edema during pregnancy?

See page 66.

What do you mean by proteinuria? What does it signify?

How would you interpret in dipstick? (Fig. 5.4)

- Protein excretion in urine is defined as proteinuria.
- ≥ 300 mg of protein in 24-hour urine, or persistent urinary protein of >30 mg/dL, or a protein:creatinine ratio of ≥ 0.3 in a random (spot) urine sample, is



Fig. 5.3: Edema over the vulva.



Fig. 5.4: Urine protein by DIPSTICK.

TABLE 5.4: Interpretation of dipstick (Fig. 5.4).

1	+	=	0.3	g/L	<1.0 g/L
2	+	=	1.0	g/L	<3.0 g/L
3	+	=	3.0	g/L	<10.0 g/L
4	+	=	10.0	g/L	or more

considered significant proteinuria. Where facilities of 24 hours urine examination or spot urine protein creatinine ratio is not available, a simple automated reagent dipstick device value of $\geq 1+$ is considered significant proteinuria.

- Proteinuria signifies impaired renal function.
- Interpretation of dipstick (**Table 5.4**)

Previously, 24-hour urine collection was gold standard for measuring proteinuria. It has problems of being time consuming, inconvenient to woman, incomplete in most cases and delay in diagnosis for which, now spot sample protein creatine ratio or albumin creatinine ratio are recommended to quantify proteinuria.

Enumerate the other causes of proteinuria

- Contamination
- Urinary tract infection
- Renal disease
- Connective tissue disorder
- Orthostatic proteinuria.

What is heat and acetic acid test?

- **Qualitative:** 'Heat and acetic acid test' is a qualitative test by which the presence of protein (albumin) is detected in urine.
- A test tube is filled with urine up to three-fourth, and the upper part of urine is boiled. The boiled part may become cloudy. 5 drops of 10% acetic acid are added to it. Disappearance of turbidity indicates presence of phosphate and if the turbidity persists it indicates presence of albumin. Severity of turbidity signifies the amount of *protein* present in urine. In presence of excess protein (10–15 g/L) urine becomes solid on boiling.
- **Quantitative:** By Esbach's albuminometer, quantitative estimation of albumin is done.

What is the sequence of development of the features of preeclampsia?

Occult edema first (as evidenced by excessive weight gain) → appearance of hypertension → visible edema (pitting

edema over ankles) → proteinuria at last (last feature to develop).

State the reasons for development of edema, hypertension and proteinuria in preeclampsia

- **Edema:** Due to extracellular sodium retention.
- **Hypertension:** As a result of vasospasm through a complex mechanism.
- **Proteinuria:** Due to specific changes in kidney—glomerulus endotheliosis resulting escape of protein.

What is the incidence of preeclampsia?


Varies from 5 to 10%, primi—10%, multi—5%.

RISK FACTORS

Predisposing factors (risk factors) for development of preeclampsia

- **High risk factors:**
 - Hypertensive disease during previous pregnancy.
 - Preexisting hypertension, chronic renal disease or connective tissue disorder.
 - Autoimmune disease such as SLE and antiphospholipid syndrome.
 - Diabetes Type 1 or 2.
 - Multiple pregnancy.
- **Moderate risk factors:**
 - Nulliparity.
 - Age—35 years or older.
 - Sociodemographic characteristics (low socioeconomic status, African American race).
 - Personal history factors (prior adverse pregnancy outcome, low birth weight or small for gestational age)
 - Pregnancy interval of >10 years.
 - Obesity: BMI >30 kg/m².
 - Family h/o hypertension or preeclampsia, 3-4-fold increase in first degree relative of the woman suffering from eclampsia.
 - Polyhydramnios.
- **Other risk factors:**
 - Severe anemia.
 - Hydatidiform mole.
 - Severe Rh-incompatibility.
 - Assisted with reproductive technology.
 - Obstructive sleep apnea.

Predictive Test for preeclampsia, see page 87.

Flowchart 5.1: Development of preeclampsia in two stages.

■ ETIOPATHOLOGY

Etiological basis of preeclampsia:

It is the **deficient trophoblastic invasion** of spiral arteries which appears to be the etiology and the vascular dysfunction is said to be the prime pathophysiology. The decidual spiral arteries are invaded by trophoblasts in normal pregnancy and the endothelium and muscular wall are replaced by trophoblasts to create **low-resistance** vessels which is the unique feature.

In preeclampsia trophoblast invasion is patchy and the muscular walls are retained in spiral arteries resulting in small caliber vessel with high resistance (See Chapter 45).

Genetic factor and altered immune response may be the reason of this defective invasion.

Development of preeclampsia (Flowchart 5.1)

Preeclampsia is developed in **two stage disease**. In the **first stage** patchy invasion of trophoblasts occurs and the muscular wall of spiral arteries are retained which prevents high flow, low impedance placental circulation resulting in ischemia. In the **second stage** oxidative stress and inflammatory stress occurs due to uteroplacental ischemia. This is associated with involvement of secondary mediators which leads to endothelial dysfunction and vasospasm. Coagulation system is also activated due to this process. This disease process of the endothelial cells spread across multiple areas, thus in true sense preeclampsia involves multiple organs simultaneously making it a multisystem disorder.

State the basic pathophysiology in preeclampsia and eclampsia involving the organs.

In normal pregnancy, there is marked peripheral vasodilatation which causes fall in total peripheral

resistance and a reduction in blood pressure in spite of increased cardiac output and blood volume. This vasodilatation is due to reduced vascular sensitivity to vasoconstrictors such as angiotensin and enhanced production of vasodilator substances such as nitric oxide (NO) and prostacyclin (PGI₂) by vascular endothelial cells. In preeclampsia, vessels show enhanced sensitivity to vasoconstrictors and reduced sensitivity to vasodilators that results in characteristic **vasospasm**. In preeclampsia, there is also reduction in synthesis of NO and PGI₂ and increase in production of endothelin-1 by vascular endothelium which not only causes vasospasm, but results in activation of platelets.

Thus, basic abnormalities which are found in preeclampsia are (1) **vasospasm** (2) **endothelial cell dysfunction** with subsequent (c) **platelet activation and microaggregate formation**. These basic changes account for many of the pathological features of preeclampsia and eclampsia.

Outline the pathological changes in vital organs of preeclampsia and eclampsia (Fig. 5.5)

- **Placenta:** Acute atherosclerosis of spiral arteries with platelet microaggregates and larger thrombosis resulting in IUGR and causing uteroplacental insufficiency in labor.
- **Kidney:** Characteristic lesion is *glomeruloendotheliosis* which is comprised of endothelial and mesangial cell swelling, with basement membrane inclusions but little disruption of renal epithelial podocytes. This type of lesion is not seen with hypertension due to other causes. This lesion results in proteinuria, decreased glomerular filtration rate (GFR), decreased renal clearance of uric acid and oliguria. Patients may develop renal failure (acute tubular necrosis and cortical necrosis).
- **Liver:** Subcapsular hemorrhage and periportal necrosis are the characteristic findings which are found in severe form. There are elevated liver enzymes (EL), serum glutamic-oxaloacetic transaminase (SGOT) [aspartate aminotransferase (AST)] and lactate dehydrogenase (LDH). Along with hemolysis (H) and low platelet count (LP), a grave complication, i.e., HELLP syndrome is constituted (See page 89).
- **Central nervous system:** Hypertensive encephalopathy, necrosis, vasospasm, cerebral edema, hemorrhages, posterior reversible encephalopathy syndrome (PRES) and eclampsia.




Fig. 5.5: Pathological changes in vital organs in preeclampsia/eclampsia. (ARDS: acute respiratory distress syndrome; ATN: acute tubular necrosis; GFR: glomerular filtration rate; HELLP: hemolysis, elevated liver enzymes, low platelet count; HT: hypertension; IUGR: intrauterine growth restriction; PRES: posterior reversible encephalopathy syndrome)

- **Cardiovascular:** Generalized vasospasm, increased peripheral resistance and reduced central venous pressure and pulmonary wedge pressures.
- **Hematological changes:** Platelet activation, micro-aggregation and depletion, coagulopathy, decreased plasma volume and increased blood viscosity.
- **Water and electrolytes:** There is sodium and water retention. Salt retention increases extracellular fluid volume. The ultimate result is intravascular reduction and extravascular accumulation of fluid resulting in hemoconcentration.

POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME

What is PRES? (Fig. 5.6)

PRES refers to posterior reversible encephalopathy syndrome. PRES is mostly found in eclampsia but their incidence in preeclampsia is 20%.

There may be variable neurological symptoms and signs, e.g., headache, altered consciousness, visual abnormalities and seizures. The typical lesion in MRI (Fig. 5.6) is seen as hyper-intense lesion (white areas) involving the posterior brain—the occipital and parietal cortices but other areas (basal ganglia, brainstem and



Fig. 5.6: MRI of a primigravida patient with eclampsia with recurrent convulsion showing multifocal patchy T2 FLAIR hyperintensity areas at bilateral frontal, parietal and temporal cortex—suggestive of PRES. (MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; PRES: posterior reversible encephalopathy syndrome)

cerebellum) may be involved. These lesions represent cerebral vasogenic edema. The lesions are found in severe diseases and patients having neurological symptoms. PRES is usually reversible, but in 25% cases the lesions

may be due to cerebral infarctions with persistence nature.

Treatment includes antihypertensives, antiepileptics and long term neurological follow up.

Eye changes in preeclampsia

What are the eye changes (ophthalmoscopic findings) in preeclampsia?

- There may not be any eye change in mild preeclampsia.
 - In severe form (1) retinal edema, (2) arteriolar constriction and changes of ratio of vein and artery from 3:2 to 3:1 and (3) nicking of veins.
- Retinal hemorrhages, exudates and papilledema are characteristics of hypertensive encephalopathy and rarely found in preeclampsia.
- **Blindness** in preeclampsia– see page 89.

PREDICTION OF PREECLAMPSIA AND ECLAMPSIA

How would you predict (screening test) who is susceptible to developing preeclampsia and eclampsia (prediction of preeclampsia)?

Currently no screening test is predictably reliable. However, some combination of tests is promising.

- By identifying pregnant women who have the **risk factors**. Taking medical history as predictor test is recommended.
- By screening test like **provocative pressor tests**, e.g., roll over test, isometric exercise test and angiotension II infusion test.
- A variety of **Biomarkers** have been proposed for the development of pregnancy in later weeks (see later).
- With the help of **USG color Doppler** as written below (Fig. 5.7A).

Provocative response tests

- **Roll over test:** As described by Gant et al., 1974 this is a clinical test done at 28–32 weeks of pregnancy to predict the development of preeclampsia in later weeks. Diastolic blood pressure of the woman is recorded first after 15 minutes of rest on left lateral position. Diastolic blood pressure is again recorded after turning her in supine position for 2–5 minutes. The test is said to be positive if there is rise of BP by 20 mm Hg.
- **Isometric exercise test:** Based on some principle by squeezing a handball.




Fig. 5.7A: Uterine artery Doppler for screening for PE at 21 weeks (normal finding) (IUGR: intrauterine growth restriction; PE: preeclampsia)

Courtesy: Prof Kushagraadhi Ghose, IFM and Prof Kamal Oswal, HOD, Radiodiagnosis, VIMS, Kolkata.

- **Angiotension II infusion test:** Increasing dose is infused IV and hyper tensive response is quantified. Recent observation (2014) shows the sensitivities of these three tests is 55–70% and specificity up to 85%.

Other predictive tests (Biomarkers)

- **Fetal-placental unit endocrine dysfunction markers:** HCG, Pregnancy associated protein A (PAPPA), Inhibin A, Activin A.
- **Renal dysfunction markers:** Increases serum uric acid, microalbuminuria.
- **Endothelial dysfunction and oxidant stress markers:** Proangiogenic and antiangiogenic markers. Proangiogenic factors such as placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) begin to drop before clinical development of preeclampsia. At the same time, levels of some antiangiogenic factors like sFlt-1 (FMS-like tyrosine kinase receptor-1) and soluble endoglin [sEng (endoglin)] increase and their rise becomes evident 5 weeks prior to the onset of PE.

UTERINE ARTERY DOPPLER

Prediction by USG color Doppler of uterine artery

Inadequate or incomplete trophoblast invasion of the spiral arteries is a constant feature in women with preeclampsia. It can be diagnosed by color Doppler. Uterine artery Doppler performs better in the second trimester than in




Fig. 5.7B: Uterine artery with notching (Early IUGR).

Courtesy: Prof Kushagradhi Ghose, IFM and Prof Kamal Oswal, HOD, Radiodiagnosis, VIMS, Kolkata.

the first trimester for identification of severe or early onset PE.

A high mean uterine artery Doppler PI (pulsatility index) multiple of medians (MOM) detects severe PE with a sensitivity of 78% and specificity of 95%.

Presence of notching (Fig. 5.7B) on maternal uterine artery Doppler (both right and left) at 22–24 weeks of gestation will identify more than 80% of women who will develop preeclampsia in later weeks with a false positive rate of only 5%. Notching is replaced by pulsatility index recently.

USG screening test is useful in the women who have risk factors and is less important in predicting low risk women.

First trimester low serum PIGF, high uterine artery pulsatility index, and other maternal parameters can predict development of preeclampsia in >90% cases (ACOG 2020).

■ DIAGNOSIS OF PREECLAMPSIA

Mention the points in favor of diagnosis of preeclampsia

- Presence of predisposing factors as mentioned previously
- Onset of the disease in the second half of pregnancy >20 weeks.
- Preeclampsia is a syndrome of more signs than symptoms. The symptoms appear in the late phase of the disease.

Symptoms may be:

- Persistent swelling of legs is not relieved by rest, gradually progressing to the face, abdominal wall, vulva and the whole body.
- Headache.
- Epigastric and right upper abdominal pain.

Signs are:

- High blood pressure. (Table 5.2)
- Abnormal weight gain.
- Features of fluid retention as evident from rapid abnormal rapid weight gain and non-dependent edema.
- Tenderness on right upper quadrant.
- Brisk reflexes.
- Presence of ankle clonus (more than three beats).
- Height of the fundus may be less than the period of amenorrhea due to IUGR and/or oligohydramnios (a feature of placental insufficiency).

■ INVESTIGATIONS

What investigations do you want to do in a case of preeclampsia?

- *Urine for protein:* By dipstick and heat acetic acid test.
 - If dipstick ≥ 1 + $\begin{cases} \rightarrow 24 \text{ hours urine} \\ \rightarrow \text{Spot protein: Creatinine ratio} \end{cases}$
- *24-hour urine:* Total protein and protein: creatinine clearance.
- *Serum uric acid:* Level >4.5 mg% is highly suggestive of preeclampsia. Uric acid is also called *biochemical marker* of preeclampsia. Hyperuricemia precedes proteinuria. It is of value in distinguishing PIH from chronic hypertension.
- Complete blood count including platelet count, fibrinogen level (if platelets counts are low). Peripheral blood smear to diagnose hemolysis (features of hemolysis—fragmented red blood cells (RBCs), spherocytes and reticulocytes).
- Liver function test.
- Blood for urea/creatinine, electrolytes.
- **Soluble fms like tyrosine kinase (sFlt-1):** PIGF ratio (sFlt-1: PIGF ratio)

Very recently, placental growth factor (PIGF) or soluble fms like tyrosine kinase (sFlt-1): PIGF ratio testing are recommended in relation to diagnosis and timing of delivery for preeclampsia. For diagnosis and need of delivery of preeclamptic mother low PIGF value has

high sensitivity and negative predictive value within 14 days. sFlt-1: PIGF ratio of <38 excludes development of preeclampsia within 7 days. In suspected preeclampsia, estimation of PIGF or sFlt-1: PIGF ratio is useful in between 20 and 34⁺⁶ weeks for termination issue.

Ultrasound: Fetal size, volume of liquor amnii and fetal Doppler study.

■ COMPLICATIONS OF PREECLAMPSIA

What are the complications of preeclampsia?

- Maternal complications
- Fetal complications

Maternal complications:

Antenatal:

- Eclampsia
- Accidental hemorrhage (Abruptio placentae)
- Cerebral hemorrhage/PRES (see page 100)
- Cardiac failure
- Oliguria and anuria
- HELLP syndrome
- *Eye complications:* Scotoma, blurring of vision, diplopia are common. Blindness is less common.
- Coagulation failure
- Preterm labor.

Intranatal:

- Eclampsia, PPH

Postnatal:

- Eclampsia, shock

Fetal complications:

- Intrauterine growth restriction
- Intrauterine death
- Asphyxia
- Prematurity

Blindness in preeclampsia and eclampsia

- **Scotoma, blurring of vision or diplopia** which are common eye problems usually improve with lowering blood pressure or with MgSO₄ therapy.
- **Blindness** is uncommon and usually reversible. Blindness is rare with preeclampsia; the incidence may be up to 15% in eclampsia. Three areas may be involved, e.g., occipital lobe, lateral geniculate nuclei, and the retina. **Retinal blindness** is due to infarction or detachment. May be asymptomatic if there is any visual problem it usually improves. In rare cases of retinal artery occlusion there may be permanent blindness.

Occipital blindness also known as “amaurosis” is due to either edema or infarction and resolves completely except in rare cases of extensive cerebral infarctions.

- Blindness in severe PE is due to retinal detachment and in eclampsia it is almost due to occipital lobe edema. Prognosis is good in both cases and regains vision within 1–2 weeks postpartum.

Remote complications of preeclampsia

- **Recurrent preeclampsia:** Five times more common (25%).
- **Chronic hypertension:** 20–40%. Those mothers who develop chronic hypertension have either familial diathesis or personal predisposition.

■ HELLP SYNDROME

What is HELLP syndrome?

- HELLP syndrome is an acronym for *hemolysis, elevated liver enzyme and low platelet* counts and a subsyndrome of severe form of preeclampsia (Weinstein 1982).
- It is rare but may occur in up to 10–15% cases of preeclampsia. HELLP syndrome mostly occurs in third trimester, but in 30% cases it is first expressed or progresses postpartum. In 15% cases of HELLP syndrome there may be insidious and atypical onset without hypertension or proteinuria (ACOG 2020).
- *Hemolysis* is due to the passage of red cells through partially obliterated vessels (microangiopathic hemolysis), as evidenced by schistocytes in blood smear, hyperbilirubinemia and absent plasma haptoglobin. *Elevated liver enzymes* are due to liver dysfunction. SGOT or AST and LDH are mostly elevated. LDH increases to 600 IU/L or more. AST and ALT are increased more than twice the upper limit of normal. *Low platelet count* (100–10⁹/L) is a late feature and is probably due to platelet aggregation and platelet deposition at the sites of endothelial damage.
- In 90% cases, presenting symptoms are right upper abdominal pain and malaise and in 50% cases there is nausea and vomiting.
- **Classification:** *Partial*—one or two abnormalities, *complete*—all three abnormalities present.
- **Complications:** The chance of hepatic hematoma and rupture of liver is increased. The other complications are eclampsia, placental abruption, acute kidney injury, pulmonary edema, stroke, coagulation disorder, acute respiratory distress syndrome and sepsis. HELLP syndrome is associated with high

perinatal and maternal mortality and once diagnosed, needs aggressive treatment usually by termination of pregnancy. Stroke is commonest cause of death in HELLP syndrome (45%). The complication rates of HELLP syndrome are much higher than those of the isolated preeclampsia. For this reason, HELLP syndrome is sometimes described under “**atypical preeclampsia—eclampsia** (Sibai 2009).”

- **Management** is on the line of severe preeclampsia, i.e., antihypertensive, prophylactic anticonvulsive, close monitoring and delivery (page 91). For women with HELLP syndrome, delivery should be undertaken shortly after initial maternal stabilization. Before 34 weeks, if maternal and fetal condition remains stable a course of steroid may be completed before termination. However, the use of corticosteroids for the specific purpose of treating HELLP syndrome is not recommended.

■ IMPENDING ECLAMPSIA

What do you mean by “fulminant preeclampsia” or “imminent eclampsia” or “impending eclampsia?”

It is a state of preeclampsia either from the onset or appears in the case of a women already suffering from preeclampsia when there is every possibility of occurrence of eclampsia, convulsion or coma at any moment.

Features of fulminant preeclampsia/imminent (impending) eclampsia

These are **actually the features of “severe preeclampsia”**

Symptoms:

- Rapid swelling
- Headache, nausea
- Visual disturbances—blurring, dimness, diplopia, and scotoma.
- Epigastric pain
- Restlessness, trembling and twitching
- Feeling unwell
- Low urinary output.

Signs:

- **BP:** Sudden rapid rise of BP
- Facial edema
- Excitement
- Hyperreflexia
- Tenderness on upper abdomen.
- Twitching and tremor restlessness, sensorium deranged.

How will you manage a case of fulminant preeclampsia?

- Patient is brought to eclampsia room immediately. Antihypertensives are administered and prophylactic anticonvulsant therapy with MgSO_4 is started.
- Patient is managed on the line of eclampsia with proper monitoring.
- If the baby is mature, immediate termination is done. If the baby is premature and the patient's condition is stabilized, then the pregnancy is terminated after completing the course of corticosteroids.
- When the patient's condition has not improved, immediate termination is done irrespective of period of gestation.

■ PREVENTION OF PREECLAMPSIA

How will you prevent preeclampsia?

Preeclampsia is not completely a preventable disease but its severity and complications can be prevented by:

- Screening of high-risk cases
- Adequate antenatal care.
- Regular exercise during pregnancy.
 - Aspirin 75–150 mg daily from 12 weeks until delivery is given to high-risk mothers and to those with more than one moderate risk factor for the prevention of preeclampsia (in selected cases).
- **Calcium** supplementation (1.5–2.0 g elemental calcium/day) particularly in populations with dietary deficiency of calcium for the prevention of preeclampsia for all women, especially for high risk of PE.
- Antioxidants, vitamin C, vitamin E are also suggested for at risk mother, but not recommended by ACOG.
- Severity can be prevented by detecting the disease at an early stage.
- There is no evidence that bed rest or salt restriction reduces the risk of preeclampsia.

Early diagnosis of preeclampsia

During routine prenatal visit, some women without overt hypertension may show new onset increase in BP. (diastolic >80 but <90 mm Hg) or sudden weight gain (>2 pounds/week) and is advised to 7 day interval visit and is looked for development of PE.

■ MANAGEMENT OF PREECLAMPSIA

Principles of Management

- Early diagnosis even in symptomless condition
- To be aware of the complications
- To maintain blood pressure within the target value using antihypertensives
- To consider the use of anticonvulsant in severe variety
- To take decision whether to admit or to do home management with regular antenatal checkup and vigilance
- To terminate in optimal time to prevent maternal and fetal complications
- Postnatal follow up and advice

■ ADMISSION OF PATIENT SUFFERING FROM PREECLAMPSIA

When should you admit a patient suffering from preeclampsia?

Ideally, all established cases of preeclampsia should be admitted as soon as diagnosed for bedrest, for more intense monitoring and for better management. In practice, it is not always possible to accommodate large number of patients in hospital. Therefore, admission in hospital is restricted to the following group of patients.

- All cases of **severe preeclampsia** (BP 160/110 mm or more).
- In non-severe variety (BP 140/90 to 159/109 mm Hg) patient is admitted if clinical concerns for the well-being of the woman or baby or if high risk of adverse events suggested by full PIERS (at any time during pregnancy) or PREP-S (Prediction of Risk in Early-onset Pre-eclampsia-Survival) (only up to 34 weeks of pregnancy) **risk prediction models** (NICE 2019).
- In all cases of **37 completed weeks** of gestation.

■ ADVICES OF HOME MANAGEMENT

What advice should be given to the patient in case of home management?


- A close out patient management and a good home support is needed for pregnancy with nonsevere variety remote from term.
- Adequate bed rest is about 10 hours (8 hours night, 2 hours in the day), preferably in left lateral position.
- High protein diet with fluid and no extra salt.

- **Anti-hypertensives:** Antihypertensive is offered if BP remains above 140/90 mm Hg (NICE 2019). **Target BP** is 135/85 mm Hg or less on antihypertensive treatment. Oral labetalol is the first line of treatment, next is Nifedipine, Methyl dopa is given if labetalol or nifedipine not suitable.
- Patients should be warned regarding the **ominous features** of fulminating preeclampsia and should attend the hospital immediately if any feature develops.
- BP is measured daily or every 48 hours by the house physician.
- Dipstick proteinuria testing is done and repeated if clinically indicated, e.g., if new symptoms and signs develop or uncertainty over diagnosis.
- To attend **antenatal clinic every week or more frequently**.
- Full blood count, platelet count liver function and renal function test including uric acid twice a week.
- **Fetal assessment:** Auscultation in every visit: Ultrasonography at diagnosis and repeat every two weeks if normal: Fetal size, amniotic fluid volume and color Doppler
Antenatal cardiotocography (CTG) at diagnosis and then only if clinically indicated.
In majority of the cases BP is controlled and pregnancy can be continued to 37 completed weeks, when the patient is admitted.

■ FOLLOWING ADMISSION

Components of conservative management following admission.

- **Rest:** Reduced physical activity throughout day in any lateral position (preferably left). However, absolute bed rest is not desirable (ACOG 2013).



Reduced physical activity is beneficial but evidence is not obvious.

- **Diet:** Adequate protein and calorie diet, no extra salt and water as per requirement (no need of restriction of dietary salt intake). Vitamin D, C and E supplementation are not recommended for prevention of preeclampsia and eclampsia.

- **Medications:** Other than routine iron, folic acid and calcium, following may be needed.
 - **Antihypertensives:** Role of antihypertensive to improve maternal and fetal outcome is debatable in nonsevere variety. It is started if BP remains above 140/90 mm Hg (NICE 2019 recommendation).
Oral labetalol is the first line of treatment, next is nifedipine, methyl dopa is given if labetalol or nifedipine are not suitable. **Target** is to keep systolic BP 135 and diastolic BP 85 mm Hg or less (**Table 5.5**).
 - **Injection MgSO₄** is given in severe preeclampsia (prophylactic anti-convulsant—regime same as eclampsia, page 100). When systolic BP is <160 mm Hg and a diastolic BP is <110 mm Hg and there is no maternal symptom, MgSO₄ is not universally given for the prevention of eclampsia.
 - **Laxative:** Stool softener, if there is constipation.
 - **Diuretics** (particularly thiazide): Limited value as they impair placental insufficiency and not recommended. May be used in (1) heart failure, (2)

TABLE 5.5: Antihypertensive drugs used in pregnancy.

Drug	Mechanism of action	Dose and route	Adverse effects	Comments
Labetalol	• A combined alpha and beta blocker. By blocking α-receptors in peripheral arterioles, it reduces peripheral resistance and concurrent β-blockade protects the heart from reflex sympathetic drive normally induced by peripheral vasodilatation. Onset of action 1–2 minutes. • Maximum effect of Labetalol is reached within 5 minutes after • IV injection, peak at 30 minutes and persists for 4 hours	• Used both in oral and IV route. Oral dose—100–400 mg, twice or thrice daily orally and can be used up to 1,200 mg/day, even maximum up to 2,400 mg/day • IV route is initial choice in severe hypertension and orally in expect-ant management • Started with 20 mg IV bolus, if BP not reduced within 10 minutes, it is followed by 40 mg and then 80 mg every 10 minutes up to total dose of 220 mg. It can be given up to 300 mg per treatment cycle (ACOG 2020) • For infusion starting dose is 20 mg/h*	• May cause fetal/neonatal bradycardia • It is better avoided in asthma, heart disease and congestive heart failure • It is safe in pregnancy	• First line of treatment and most popular • Drug of choice in severe hypertension and in expect-ant management. Can cause rapid reduction of BP. Tachycardia is less common with fewer adverse effects
Methyldopa	It is a centrally acting drug with delayed onset of action (4–6 hours). Reduces sympathetic outflow	Only orally given. Dose: 250–500 mg, twice or thrice or 6 hourly daily, maximum 2 g daily	It has side effects like sedation and depression. It causes postpartum depression and should not be prescribed in postpartum period. It has no major side effect, well tested, safety proven	Commonly used drug. Useful in chronic hypertension and moderate PIH. Not suitable for severe preeclampsia
Nifedipine	• A calcium channel blocker (peripheral vasodilator) with quick onset of action (5–10 minutes) • May be used instead of labetalol and appears to be safe in late pregnancy. Onset of action is 5–10 minutes, peak at 30 minutes and action persists for 6 hours	Only oral route. 10 mg orally thrice daily. In eclampsia starting dose is 10–20 mg followed by another dose after 20 minutes if not controlled, then every 2–6 hourly with maximum daily dose 180 mg (ACOG 2020). <i>Sublingual route is not recommended</i>	• May cause nausea, tachycardia, hypotension. It may cause severe headaches that mimics worsening disease. • Nifedipine should be used cautiously as along with MgSO₄ it will cause maternal hypotension, profound muscle weakness and fetal distress	• Useful in severe hypertension alternate to labetalol. Nifedipine lowers • BP quickly than labetalol. • Drawback is IV preparation is not available

Contd...

Contd...

Drug	Mechanism of action	Dose and route	Adverse effects	Comments
Hydralazine (Dralaz)	Acts as a peripheral vasodilator, rapid onset of action (10–20 minutes)	- Only IV route. - Used in imminent eclampsia, eclampsia and hypertensive crisis. - Initially 5 mg IV and can be repeated 20–40-minute intervals with 5–10 mg dose until a satisfactory result is achieved or up to total dose of 30 mg - Constant infusion 0.5–10 mg/h - Consider 500 mL crystalloids preload or with the first dose—hydralazine (NICE 2019)	Side effects are palpitation, headache, tachycardia, nausea and vomiting	- It also decreases BP quickly. Maternal and neonatal outcomes are similar with hydralazine and labetalol. - Hydralazine causes more tachycardia and palpitations. - Hypotension—labetalol results more bradycardia. - Both causes maternal hypotension

• *Others: Other second line antihypertensive drugs used in eclampsia.* Nitroprusside or nitroglycerine, nimodipine, verapamil and ketanserin, etc., are used in refractory cases (consultation with anesthetist or physician needed).

• **Diuretics (frusemide)** are not used in pregnancy as it compromises placental perfusion and is only used to treat pulmonary edema, heart failure.

• **ARBs** (Angiotensin receptor blockers), **ACE inhibitors** (Angiotensin-converting enzyme inhibitors) are alleged to be associated with fetal anomalies and contraindicated in pregnancy and preconception period β -blockers (atenolol and propranolol) are also not recommended in pregnancy.

• **IV infusion of labetalol:** Is started at a rate of 20 mg/h and in every 30 minutes dose is doubled till a satisfactory response is obtained or a dose 160 mg/h is reached. Commonly used IV fluids are Ringer lactate, 5% Dextrose or normal saline.

How to prepare?

• **By IV drip:** From a 100 mL bag of normal saline (0.9%) 40 mL is withdrawn. 200 mg labetalol (40 mL) (10 ampoule, each ampoule contains 4 mL, each mL contains 5 mg = total 200 mg) is added to remaining 60 mL in the bag of normal saline. Final concentration is 2 mg/mL. IV infusion is started at 10 mL/h (20 mg/h).

• **Using infusion pump:** Injection labetalol 40 mL (10 ampoule—each amp contains 4 mL, each mL contains 5 mg = total 200 mg) + 10 mL normal saline in 50 cc syringe. The syringe is fitted in infusion pump and started in 5 mL/h.

• By adjusting the rate (doubling, maintaining or halving) blood pressure is stabilized as required every 15–30 minutes to a maximum dose of 80 mL/h (160/mg h).

(BP: blood pressure)

pulmonary edema, (3) massive edema and (4) with certain antihypertensives.

■ Maternal monitoring:

- Maternal wellbeing, appearance of new symptoms and signs—severe headache, visual changes, epigastric pain and shortness of breath.
- Amount of urine every day (oliguria means <400 mL of urine in 24 hours).
- BP measurement twice daily, at least four times a day in severe hypertension and every 15–30 minutes until BP is <160/110 mm Hg.
- Weight measurement alternate day.
- Dipstick proteinuria is tested. Repeated if clinically indicated, e.g., new symptoms/signs or uncertainly over diagnosis.
- Urine for 24-hour protein or protein creatinine ratio.

- Complete blood count, platelet count, peripheral blood smear, renal function test (urea, creatinine, and uric acid), electrolytes, liver function test—twice or thrice weekly. Serum creatinine is done daily, where creatinine is elevated beyond twice its normal value.
- Ophthalmoscopic examination.


■ Fetal assessment:

- **Fetal wellbeing** is assessed by clinical examination including FHS auscultation (done twice daily) and daily fetal movement count. Other parameters such as nonstress test CTG, biophysical score Doppler velocimetry [in suspected fetal growth rate (FGR)] is done once weekly depending upon clinical findings (page 38).

- **Fetal growth** is assessed clinically and with the help of USG every week. Frequency is altered depending on clinical condition.

Flowchart 5.2 provides an algorithm for approaching the patient with pregnancy induced hypertension.

Flowchart 5.2: Algorithm showing approach to management of pregnancy induced hypertension.



Bedside Clinics in Obstetrics

Clinics to Care with Illustrations

Salient Features

- This book has been written keeping in mind the requirements of students preparing for theoretical, oral, and practical examinations. Although primarily intended for MBBS students, it is equally valuable for postgraduate students, with content aligned to the latest National Medical Commission (NMC) competency-based curriculum
- The book presents individual clinical cases in a systematic sequence, covering case taking, history, clinical examination, diagnosis, and management. The subject matter is presented in a reader-friendly question-and-answer format and is supported by a large number of colored illustrations, original clinical photographs, and tables. These features facilitate better understanding of the subject and help students perform confidently in examinations
- Clinical methods, examination maneuvers, modern investigations, partography, ultrasonography, cardiotocography, surgical procedures, and obstetric and gynecological instruments are comprehensively illustrated with more than 800 original photographs and 622 colored hand-drawn illustrations
- The chapter on instruments has been completely revised and redesigned in this edition with a more practical, visually rich, and examination-oriented approach to facilitate easier identification, understanding, and recall
- In this sixth edition of *Bedside Clinics in Obstetrics*, every chapter has been extensively revised and updated in accordance with the latest evidence and clinical guidelines
- Several new features have been introduced, including clinical algorithms in most chapters to promote rapid understanding and clinical decision-making, as well as high-yield points at the end of every chapter for quick revision and examination preparation
- Several new topics have been incorporated along with recent Government of India programs and the latest maternal and child health indicators, including data from the Registrar General of India and NFHS-6 (May 2026), ensuring that the content remains current, evidence-based, and relevant to present-day clinical practice
- Besides serving as a comprehensive examination companion, this book is an invaluable reference for practicing obstetricians and gynecologists, helping them approach diverse clinical scenarios with confidence while remaining updated with contemporary obstetric practice.

Arup Kumar Majhi MD DNB FICOG is a renowned Professor and also Former Head, Department of Obstetrics and Gynecology, RG Kar Medical College and Hospital, Kolkata, West Bengal, India. From the very early days of his medical career, he had a special interest in teaching both undergraduate and postgraduate students. He is well known for his extraordinary teaching capability, clinical acumen, decision making, surgical skills, and sincerity to the patients and students. Dr Majhi is an Examiner for both undergraduate and postgraduate examination of different universities of India, including DNB. He is very popular in the obstetrics and gynecology fraternity and also amongst his students for his academic and teaching skills. He is Recipient of multiple awards. He is also the Author of two other useful books—*Bedside Clinics in Gynecology* and *Operative Obstetrics: An Illustrated Manual*. Both the books are published by M/s Jaypee Brothers Medical Publishers (P) Ltd, New Delhi, India. He was the National President, ISOPARB (Indian Society of Perinatology and Reproductive Biology), Past President, Kolkata chapter, ISOPARB, Past Vice President, ISOPARB and Past President, Bengal Obstetric & Gynecological Society. A regular contributor to various journals, he has to his credit more than 110 articles in national and international journals and books. He is the Emeritus Editor of Indian Journal of Perinatology and Reproductive Biology and past National corresponding Editor of Journal of Obstetrics and Gynaecology of India (FOGSI Journal). Presently, he is a Governing Council Member, Indian College of Obstetrics and Gynaecology, academic wing of FOGSI.



Buy from ejaypee



**JAYPEE
BROTHERS**

Shelving Recommendation
OBSTETRICS & GYNECOLOGY

ISBN 978-93-0952-930-6

